lenvatinib and pembrolizumab compared to sunitinib for advanced renal cell carcinoma
Published 3 years ago • 817 plays • Length 10:06Download video MP4
Download video MP3
Similar videos
-
0:49
clear: lenvatinib and pembrolizumab in advanced renal cell carcinoma
-
1:44
assessing lenvatinib with pembrolizumab in advanced renal cell carcinoma
-
3:26
extended follow-up from a trial of pembrolizumab plus axitinib for advanced renal cell carcinoma
-
7:05
health-related quality of life with lenvatinib plus pembrolizumab for patients with advanced rcc
-
2:06
lenvatinib plus pembro for arcc - update on the clear study
-
5:14
lenvatinib plus pembrolizumab after progression on immune checkpoint inhibitors for metastatic rcc
-
4:39
avelumab and axitinib vs sunitinib in treating advanced renal cell carcinoma
-
9:30
study on avelumab and axitinib vs sunitinib in the treatment of advanced renal cell carcinoma
-
0:59
combining lenvatinib & pembrolizumab for non-clear cell rcc: keynote-b61 study rationale
-
1:45
keynote-426: pembrolizumab and axitinib vs sunitinib in advanced renal cell carcinoma
-
2:41
leap-011: exploring first-line pembrolizumab lenvatinib for advanced urothelial carcinoma
-
4:17
longer term outcomes with pembrolizumab plus axitinib for advanced rcc
-
3:36
sunitinib vs cabozantinib, crizotinib, or savolitinib for metastatic papillary rcc
-
4:13
checkmate 214: nivolumab ipilimumab vs sunitinib for advanced or metastatic renal cell carcinoma
-
5:32
lenvatinib and everolimus for advanced rcc
-
3:21
cabosun trial: cabozantinib vs sunitinib for renal cell carcinoma
-
32:46
lenvatinib pembrolizumab in rcc, the clear trial with karine tawagi
-
7:34
frontline sunitinib compared to everolimus in metastatic renal cell carcinoma
-
8:07
tki/io comparison: lenvatinib/pembrolizumab vs cabozantinib/nivolumab vs axitinib/pembrolizumab